Phaseline

Targets › UL97

UL97: drug programs, companies and trials

2 programs from 2 companies in 4 trials: 2 Phase 2, 2 Phase 3; Infectious disease, Oncology; next expected readout Jan 2027.

Open in Phaseline: the race on UL97, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
TakedaMaribavir
Serine/threonine-protein kinase BGLF4 inhibitor; Phosphotransferase pUL97 inhibitor
UL97Phase 3Cytomegalovirus (CMV); Hematologic MalignancyJan 2027
Murdoch Childrens Research InstituteGanciclovir
Human herpesvirus 1 DNA polymerase inhibitor
UL97Phase 2Cytomegalovirus ViraemiaJun 2028

Conditions

Cytomegalovirus (CMV) (2) Cytomegalovirus Viraemia (1) Hematologic Malignancy (1)

Modalities

small molecule (2)

Companies

Murdoch Childrens Research Institute (1) Takeda (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.